Trial reportJournal of thrombosis and thrombolysis2005
Combined thrombolysis with abciximab favourably influences platelet-leukocyte interactions and platelet activation in acute myocardial infarction.
Trial report in Journal of thrombosis and thrombolysis, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 14 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn patients with acute myocardial infarction (AMI), activated platelets and altered haemostatic/fibrinolytic systems with and without thrombolytic therapy are known. Platelets thereby interact with neutrophils, stimulated endothelial cells and with monocytes leading to adverse effects on further myocardial damage. Thrombolysis in these patients is still hampered by procoagulant effects favoring early reocclusion. The additional treatment with a GPIIb/IIIa antagonist aimed to minimize early reocclusion thus improving the present therapeutic regimen.
methodsIn 38 patients with AMI, we investigated the effects of a thrombolytic regimen with half reteplase (r-PA) dose plus abciximab vs. full dose r-PA on membrane-bound adhesion molecules (CD41, CD42b, CD40, CD40L) expressed on platelets, neutrophils and monocytes as well as on soluble platelet-selectin as interaction and activation markers of these cells.
resultsThe combination group had significantly (p < 0.05) lower sP-selectin levels over 48 h vs. the group treated with full dose r-PA. After 3 h, the percentage of CD41 and CD42b positive monocytes and granulocytes as well as the percentage of CD40 positive granulocytes and the percentage of CD40L positive monocytes markedly (p < 0.01, p < 0.05) decreased in the combination group vs. data at admission compared with the r-PA group indicating less leukocyte-patelet adhesion.
conclusionsThe thrombolytic regimen with half dose r-PA and abciximab had a benefical influence on platelet activation and induced a more marked decrease of platelet-monocyte, and in part, platelet-granulocyte aggregates compared with the r-PA regimen. This could contribute to a probably lesser monocyte activation state with favourable effects on monocyte-endothelial adhesion and a consecutively possible influence of myocardial damage, a reduction of the additionally acute local inflammatory processes and a reduction of adherence of platelet-granulocyte aggregates to subendothelium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.